Please assess the completion status of the following clinical trial:

Trial Title: A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* CIU diagnosis \> 3 months (by history)~* No underlying etiology clearly defined for urticaria (main manifestation cannot be physical urticaria)~Exclusion Criteria:~* Pregnant, breastfeeding, or women not taking contraception~* Patients \< 40kg~* Treatment with any investigational agent within 30 days of screening~* Recent history of drug or alcohol abuse~* Atopic dermatitis or other skin disease associated with pruritus~* Clinically relevant major systemic disease (making interpretation of the study results difficult)~* Previously treated with omalizumab (\< 12 months since last injection)~* Patients may not take during treatment period or have been taking within the past 3 months any of the following medications/treatments: regular (daily/every other day) hydroxychloroquine, methotrexate, cyclosporine, cyclophosphamide, IVIG, or plasmapheresis~* Patients may not have been taking doxepin within the past 6 weeks regular (daily/every other day).

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab 75 mg (Type: EXPERIMENTAL): Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.).
- Omalizumab 300 mg (Type: EXPERIMENTAL): Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
- Omalizumab 600 mg (Type: EXPERIMENTAL): Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a single subcutaneous placebo injection on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).